Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Italiano, A, Nanda, S, Briggs, A, Garcia-Foncillas, J, Lassen, U, Vassal, G, Kummar, S, van Tilburg, CM, Hong, DS, Laetsch, TW, Keating, K, Reeves, JA, Fellous, M, Childs, BH, Drilon, A & Hyman, DM 2020, 'Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis', Cancers, bind 12, nr. 11. https://doi.org/10.3390/cancers12113246

APA

Italiano, A., Nanda, S., Briggs, A., Garcia-Foncillas, J., Lassen, U., Vassal, G., Kummar, S., van Tilburg, C. M., Hong, D. S., Laetsch, T. W., Keating, K., Reeves, J. A., Fellous, M., Childs, B. H., Drilon, A., & Hyman, D. M. (2020). Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers, 12(11). https://doi.org/10.3390/cancers12113246

CBE

Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, Hyman DM. 2020. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers. 12(11). https://doi.org/10.3390/cancers12113246

MLA

Vancouver

Author

Italiano, Antoine ; Nanda, Shivani ; Briggs, Andrew ; Garcia-Foncillas, Jesus ; Lassen, Ulrik ; Vassal, Gilles ; Kummar, Shivaani ; van Tilburg, Cornelis M ; Hong, David S ; Laetsch, Theodore W ; Keating, Karen ; Reeves, John A ; Fellous, Marc ; Childs, Barrett H ; Drilon, Alexander ; Hyman, David M. / Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer : An Intra-Patient Comparative Analysis. I: Cancers. 2020 ; Bind 12, Nr. 11.

Bibtex

@article{766537c94c2f4306ab04496c6b1ec596,
title = "Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis",
abstract = "Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progression (TTP) on the last prior line of therapy; GMI ≥ 1.33 is considered a threshold of meaningful clinical activity. In a retrospective, exploratory analysis among patients with advanced tropomyosin receptor kinase (TRK) fusion cancer treated with the selective TRK inhibitor larotrectinib who received ≥1 prior line of therapy for locally advanced/metastatic disease, we determined the proportion of patients with GMI ≥ 1.33; patients who had not progressed by data cut-off were censored for PFS. Among 72 eligible patients, median GMI was 2.68 (range 0.01-48.75). Forty-seven patients (65%) had GMI ≥ 1.33; 13/25 patients (52%) with GMI < 1.33 had not yet progressed on larotrectinib. Kaplan-Meier estimates showed a median GMI of 6.46. The probability of attaining GMI ≥ 1.33 was 0.75 (95% confidence interval (CI), 0.65-0.85). Median TTP on previous treatment was 3.0 months (95% CI, 2.6-4.4). Median PFS on larotrectinib was not estimable ((NE); 95% CI, NE; hazard ratio, 0.220 (95% CI, 0.146-0.332)). This analysis suggests larotrectinib improves PFS for patients with TRK fusion cancer compared with prior therapy.",
author = "Antoine Italiano and Shivani Nanda and Andrew Briggs and Jesus Garcia-Foncillas and Ulrik Lassen and Gilles Vassal and Shivaani Kummar and {van Tilburg}, {Cornelis M} and Hong, {David S} and Laetsch, {Theodore W} and Karen Keating and Reeves, {John A} and Marc Fellous and Childs, {Barrett H} and Alexander Drilon and Hyman, {David M}",
year = "2020",
month = nov,
day = "4",
doi = "10.3390/cancers12113246",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "M D P I AG",
number = "11",

}

RIS

TY - JOUR

T1 - Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer

T2 - An Intra-Patient Comparative Analysis

AU - Italiano, Antoine

AU - Nanda, Shivani

AU - Briggs, Andrew

AU - Garcia-Foncillas, Jesus

AU - Lassen, Ulrik

AU - Vassal, Gilles

AU - Kummar, Shivaani

AU - van Tilburg, Cornelis M

AU - Hong, David S

AU - Laetsch, Theodore W

AU - Keating, Karen

AU - Reeves, John A

AU - Fellous, Marc

AU - Childs, Barrett H

AU - Drilon, Alexander

AU - Hyman, David M

PY - 2020/11/4

Y1 - 2020/11/4

N2 - Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progression (TTP) on the last prior line of therapy; GMI ≥ 1.33 is considered a threshold of meaningful clinical activity. In a retrospective, exploratory analysis among patients with advanced tropomyosin receptor kinase (TRK) fusion cancer treated with the selective TRK inhibitor larotrectinib who received ≥1 prior line of therapy for locally advanced/metastatic disease, we determined the proportion of patients with GMI ≥ 1.33; patients who had not progressed by data cut-off were censored for PFS. Among 72 eligible patients, median GMI was 2.68 (range 0.01-48.75). Forty-seven patients (65%) had GMI ≥ 1.33; 13/25 patients (52%) with GMI < 1.33 had not yet progressed on larotrectinib. Kaplan-Meier estimates showed a median GMI of 6.46. The probability of attaining GMI ≥ 1.33 was 0.75 (95% confidence interval (CI), 0.65-0.85). Median TTP on previous treatment was 3.0 months (95% CI, 2.6-4.4). Median PFS on larotrectinib was not estimable ((NE); 95% CI, NE; hazard ratio, 0.220 (95% CI, 0.146-0.332)). This analysis suggests larotrectinib improves PFS for patients with TRK fusion cancer compared with prior therapy.

AB - Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free survival (PFS) on the current therapy to time to progression (TTP) on the last prior line of therapy; GMI ≥ 1.33 is considered a threshold of meaningful clinical activity. In a retrospective, exploratory analysis among patients with advanced tropomyosin receptor kinase (TRK) fusion cancer treated with the selective TRK inhibitor larotrectinib who received ≥1 prior line of therapy for locally advanced/metastatic disease, we determined the proportion of patients with GMI ≥ 1.33; patients who had not progressed by data cut-off were censored for PFS. Among 72 eligible patients, median GMI was 2.68 (range 0.01-48.75). Forty-seven patients (65%) had GMI ≥ 1.33; 13/25 patients (52%) with GMI < 1.33 had not yet progressed on larotrectinib. Kaplan-Meier estimates showed a median GMI of 6.46. The probability of attaining GMI ≥ 1.33 was 0.75 (95% confidence interval (CI), 0.65-0.85). Median TTP on previous treatment was 3.0 months (95% CI, 2.6-4.4). Median PFS on larotrectinib was not estimable ((NE); 95% CI, NE; hazard ratio, 0.220 (95% CI, 0.146-0.332)). This analysis suggests larotrectinib improves PFS for patients with TRK fusion cancer compared with prior therapy.

U2 - 10.3390/cancers12113246

DO - 10.3390/cancers12113246

M3 - Journal article

C2 - 33158040

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 11

ER -

ID: 61506913